This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Anton V. Gorbachev, Ph.D.

Co-Director of CTL CRO Laboratory

Personal Statement
Immune monitoring allows to test the efficacy of new therapies and vaccines by evaluating the immune response of each individual patient/participant during the course of the treatment. Being a global leader of immune monitoring, CTL uses the most advanced approaches to test a wide variety of immune biomarkers such as cytokines, chemokines, cytolytic molecules and antibodies involved in the ensuing immune response. As a member of CTL CRO Management Team, my role is to ensure excellent work performance by the CRO laboratory to meet the high standards set by CTL.

Education
  • M.S. Cell Biology/Microbiology, Moscow State University, Moscow, Russia, 1991
  • Ph.D. Biology, Oncology Research Center and Moscow State University, Moscow, Russia, 1995
Professional Experience/Training:
  • 11/2017-present: Co-Director, Contract Laboratory (CRO), Cellular Technology Limited, Cleveland, OH, overseeing immune monitoring by ELISPOT, ELISA and flow cytometry assays.
  • 08/2016-02/2017: Medical Science Liaison, Osiris Therapeutics, Columbia, MD. Educating health professionals in the field of advanced wound care products (placental tissue-based).
  • 10/2014-07/2016: Research Associate Staff, R&D lab, Cleveland Cord Blood Center, Cleveland, OH. Development of umbilical cord blood stem cell-based therapies for a broad spectrum of clinical indications (wound healing, cardiovascular and autoimmune diseases).
  • 2009-2014: Project Staff (Instructor), Dept. of Immunology, Cleveland Clinic, Cleveland, OH. Development and testing novel therapeutic approach based on inducing constitutive expression of CXCL9/Mig chemokine in cutaneous tumors.
  • 2006-2009: Scientist, Cleveland Biolabs Inc., Cleveland, OH. Testing the therapeutic efficacy of novel anti-cancer and anti-inflammatory compounds in murine models of cancer and contact skin allergy.
  • 2002-2006: Research Associate, Dept. of Immunology, Cleveland Clinic, Cleveland, OH. Mechanisms of T cell-mediated immune responses to contact allergens and cutaneous tumors.
  • 1998-2002: Postdoctoral Fellow, Dept. of Immunology, Cleveland Clinic, Cleveland, OH Mechanisms of T cell-mediated immune responses in the skin.
  • 1996-1998: Postdoctoral Fellow, Dept. of Microbiology, New York Medical College, New York, NY. Development of anti-idiotypic antibodies for the therapy of melanoma.
Peer-Reviewed Publications
  1. Engeman, TM, Gorbachev, AV, Gladue, RP, Fairchild, RL. Inhibition of functional T cell priming and contact hypersensitivity responses by treatment with anti-secondary lymphoid chemokine antibody during hapten sensitization. J. Immunol., 2000, 164: 5207-5214.
  2. Gorbachev, AV, Heeger, PS, Fairchild, RL. CD4+ and CD8+ T cell priming for contact hypersensitivity occurs independently of CD40-CD154 interactions. J. Immunol., 2001, 166: 2323-2332.
  3. Gorbachev, AV, DiIulio, NA, Fairchild, RL. IL-12 augments CD8+ T cell development for contact hypersensitivity responses and circumvents anti-CD154 antibody-mediated inhibition. J. Immunol., 2001, 167, 156-164.
  4. Gorbachev, AV and Fairchild, RL. Induction and regulation of T cell priming for contact hypersensitivity. Critical Rev. Immunol., 2002, 21: 451-472.
  5. Gorbachev, AV and Fairchild, RL. Regulatory role of CD4+ T cells during the development of contact hypersensitivity responses. Immunol. Research, 2001, 24(1): 69-77.
  6. Gorbachev, AV and Fairchild, RL. CD4+ T cells regulate CD8+ T cell-mediated cutaneous immune responses by restricting effector T cell development through a FasL–dependent mechanism. J. Immunol., 2004, 172: 2286-2295.
  7. Gorbachev, AV and Fairchild, RL. CD40 engagement enhances antigen-presenting Langerhans cell priming of IFN-g producing CD4+ and CD8+ T cells independently of IL-12. J. Immunol. 2004, 173(4): 2443-2452.
  8. Kish DD, Gorbachev AV, and Fairchild RL. Role of IL-2 in the regulation of effector CD8+ T cell priming for contact hypersensitivity response. J. Leukoc. Biol., 2005, 78: 725-735.
  9. Kish DD, Gorbachev AV, Fairchild RL. CD8+ T cells produce IL-2, which is required for CD(4+)CD25+ T cell regulation of effector CD8+ T cell development for contact hypersensitivity responses. J Leukoc Biol. 2005 Sep;78(3):725-35.
  10. Schenk S, Kish DD, He C, El-Sawy T, Chiffoleau E, Chen C, Wu Z, Sandner S, Gorbachev AV, Fukamachi K, Heeger PS, Sayegh MH, Turka LA, Fairchild RL. Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+CD25+ T cells. J. Immunol. 2005, 174:3741.
  11. Gorbachev AV and Fairchild RL. Activated NKT cells increase dendritic cell migration and enhance CD8+ T cell responses in the skin. Eur. J. Immunol., 2006, 36: 2494-2503.
  12. Kish DD, Gorbachev AV, Fairchild RL. Regulatory functions of CD4+CD25+ T cells from class II MHC-deficient mice in contact sensitivity responses. J. Leukocyte Biol. 2007, 82:85-92.
  13. Gorbachev AV, Kobayashi H, Kudo D, Tannenbaum CS, Finke JH, Shu S, Farber JM, Fairchild RL. CXC chemokine ligand 9/monokine induced by IFN-gamma production by tumor cells is critical for T cell-mediated suppression of cutaneous tumors. J. Immunol. 2007 Feb 15;178(4):2278-86.
  14. Gorbachev AV, Gasparian AV, Gurova KV, Gudkov AV, and Fairchild RL. Quinacrine inhibits the epidermal dendritic cell migration initiating T cell-mediated skin inflammation. Eur J Immunol. 2007 Aug;37(8):2257-67.
  15. Neznanov N, Gorbachev AV, Neznanova L, Komarov AP, Gurova KV, Gasparian AV, Banerjee AK, Almasan A, Fairchild RL, Gudkov AV. Anti-malaria drug blocks proteotoxic stress response: anti-cancer implications. Cell Cycle, 2009, 8:3960-3970.
  16. Gorbachev AV, Fairchild RL. CD4+CD25+ regulatory T cells utilize FasL as a mechanism to restrict DC priming functions in cutaneous immune responses. Eur. J. Immunol. 2010, 40 (7): 2006-2015.
  17. Kish DD, Gorbachev AV, Fairchild RL. IL-1 Receptor Signaling Is Required at Multiple Stages of Sensitization and Elicitation of the Contact Hypersensitivity Response. J Immunol. 2012, 188(4): 1761-71.
  18. Kish DD, Gorbachev AV, Parameswaran N, Gupta N, Fairchild RL. Neutrophil expression of FasL and perforin directs effector CD8 T cell infiltration into antigen-challenged skin. J Immunol. 2012. 189(5): 2191-2202.
  19. Petro M, Kish DD, Guryanova OA, Ilyinskaya G, Kondratova A, Fairchild RL and Gorbachev AV. Cutaneous Tumors Cease CXCL9/Mig Production as a Result of IFN-gamma-Mediated Immunoediting. J. Immunol. 2013. 190(2): 832-841.
  20. Gorbachev AV, Fairchild RL. Regulation of Chemokine Expression in the Tumor Microenvironment. Critical Reviews in Immunology, 2014, 34(2): 103-120.
  21. Traitanon O, Gorbachev A, et al. IL-15 Induces Alloreactive CD28- Memory CD8 T Cell Proliferation and CTLA4-Ig Resistant Memory CD8 T Cell Activation. Am. J. Transplant. 2014, 14(6): 1277-1289.